Chimerix(US:CMRX)2025-03-21 10:06Financial Performance - Chimerix reported a net loss of $23.0 million, or $0.25 per share, for Q4 2024, compared to a net loss of $18.2 million, or $0.20 per share, in Q4 2023[3] - Full-year net loss for 2024 was $88.4 million, or $0.99 per share, compared to a net loss of $82.1 million, or $0.93 per share, in 2023[5] - Total revenues for 2024 were $212,000, a decrease from $324,000 in 2023, indicating a decline of approximately 34.4%[14] Research and Development - Research and development expenses increased to $17.7 million in Q4 2024, up from $15.6 million in Q4 2023, reflecting a growth of approximately 13.5%[3] - Research and development expenses for the full year 2024 totaled $74.6 million, up from $68.8 million in 2023, marking an increase of approximately 8.5%[5] Administrative Expenses - Chimerix's general and administrative expenses increased to $7.0 million in Q4 2024, compared to $5.2 million in Q4 2023, primarily due to increased spending on commercial launch preparations[4] Capital and Assets - The company had $140.1 million in capital available to fund operations as of December 31, 2024, with no outstanding debt[2] - Chimerix's total assets decreased to $146.0 million as of December 31, 2024, down from $212.8 million in 2023[13] Acquisition - The acquisition by Jazz Pharmaceuticals is expected to close in Q2 2025 for approximately $935 million, at $8.55 per share[7] Regulatory Updates - The NDA for dordaviprone is under review with a PDUFA action date set for August 18, 2025[1]